

~~11/44.~~

(New) An expression vector comprising the DNA construct of claim ~~34~~.

~~12/45.~~

A transformed eukaryotic cell comprising the expression vector of claim ~~44~~.

~~13/46.~~

A method of producing a glycoprotein comprising:

- (a) culturing a eukaryotic cell comprising an expression vector comprising a first DNA segment comprising a nucleic acid sequence that encodes mammalian t-PA pro-sequence operatively linked to a nucleic acid sequence that encodes a pre-sequence other than a mammalian t-PA pre-sequence and a second DNA segment operably linked to the first DNA segment, wherein the second DNA segment encodes a heterologous glycoprotein;
- (b) recovering the glycoprotein from the cell culture.

REMARKS

Applicants have received and reviewed an Office Action dated September 29, 2000. By way of response, Applicants have cancelled claims 1 and 6 without prejudice and solely to expedite prosecution. Applicants reserve the right to pursue the subject matter of those claims in a continuation application. Applicants have amended claims 2, 5, 7, 9, 14, and 30. Originally filed claim 2 was dependent on now cancelled claim 1 and is now written in independent form. The amended claims are supported throughout the specification including at page 2 lines 22-31. Applicants have presented new claims 34-46. Newly presented claim 34 is originally filed claim 5 written in independent form. The newly presented claims are supported throughout the specification, including at page 2 lines 32-38, and page 12 lines 18-27 and page 13 lines 30-page 4 line 30. No new matter is presented by the amendment.

Applicants have submitted a substitute specification in compliance with 1.125 (b) and request entry of the substitute specification. The substitute specification now has a 2 cm margin at the top of the pages. The change in the margin has resulted in an increase in the number of pages of the specification but no additions or deletions of the text of the original specification

were made. Applicants have provided a marked up copy of the specification showing the shift in the text. Applicants state that no new matter has been included in the substitute specification.

Petition for Extension of Time

It is noted that a two-month petition for extension of time is necessary to provide for timeliness of the response. A request for such an extension is made extending the time for response from December 29, 2000 to February 28, 2001.

Specification

The Examiner requested a substitute specification having a top margin of at least two centimeters. Applicants have provided along with the Amendment a substitute specification with a top margin of at least two centimeters. The change in the top margin has resulted in an increase in the number of pages of specification but no additions or deletions to the original text were made. The original text was just shifted from page to page. Applicants have provided a marked up copy of the specification showing the shift of the text from page to page.

The marked up copy of the specification as filed, on any given page, could have 3 sections of text moved to different pages in the substitute specification. (1) refers to the first section of the text bounded by { 1 . (2) refers to a second section of text bounded by { 2 . (3) refers to a third section of text bounded by { 3 . At the bottom of each page of the marked up version, Applicants identify the corresponding page in the substitute specification to which the text has moved.

Claim Objection

The Examiner objected to claim 9 asserting that the claim includes an obvious grammatical error. Applicants have amended the claim as requested by the Examiner.

Rejection of Claims Under Section 112, First Paragraph

The Examiner rejected claim 15 under 35 U.S.C. § 112, first paragraph. The Examiner asserts that the specification does not fully support claims reciting another DNA segment operably linked to the first and second DNA segments. Applicants respectfully traverse this rejection.

The specification provides support for including a wide variety of DNA segments operably linked to the first and second DNA segments. The additional DNA segment can be a component of an expression vector, such as a promoter, an optional operator sequence, an optional RNA splice donor/acceptor sequence, a sequence encoding mRNA ribosome binding sites, sequences that control termination of transcription and translation, polyadenylation signals, and enhancers (specification at least at page 9, lines 3-7 and 18-20, and at page 13, lines 30-36). Example 1 at page 16, lines 12-16, describes that the constructs employed in these experiments included a promoter, a polyadenylation site, and an enhancer. The additional DNA segment operably linked to the first and second DNA segments can also encode a portion of a fusion protein. Such fusion proteins include immunoadhesins in which a coding sequence for a heterologous glycoprotein is operably linked to another heterologous protein or glycoprotein. Support for such fusion proteins can be found throughout the specification including at least at page 7, line 30, through page 8, line 17, and in the Examples at pages 15-23. Thus, the specification as filed fully supports claims reciting another DNA segment operably linked to the first and second DNA segments.

Accordingly, it is believed that claim 15 fully complies with § 112, first paragraph, and withdrawal of this rejection is respectfully requested.

The Examiner also rejected claim 23 under 35 U.S.C. § 112, first paragraph. The Examiner asserts that the specification does not fully support claims reciting glycosylation site addition variants. Applicants respectfully traverse this rejection.

The specification provides both general and detailed support for adding a glycosylation site to a protein. Such general and detailed support can be found in the specification at least at page 2, lines 16-18, at page 3, lines 1-10, at page 7, lines 3-10 and 14-19, and at page 13, lines 1-16. The detailed support includes description of protein sequences that determine N-linked and O-linked glycosylation sites and instructions that such sequences can be substituted into a protein to make a glycosylation site variant. Given this detailed of level description, one of skill in the art could insert sequences determining glycosylation sites into a protein to produce a glycosylation site addition variant. Thus, the specification as filed fully supports claims reciting glycosylation site addition variants.

Accordingly, it is believed that claim 23 fully complies with § 112, first paragraph, and withdrawal of this rejection is respectfully requested.

Rejection of Claims Under Section 112, Second Paragraph

The Examiner rejected claims 1-33 under 35 U.S.C. § 112, second paragraph. The Examiner objected to certain terms and phrases employed in claims. Applicants respectfully traverse this rejection.

The Examiner objected to the use of the terms "segment" and "sequence" in claims 1, 14, 30, and 33. The claims lack an antecedent basis for "sequence". Applicants have amended the claims to correct the lack of an antecedent basis by using the term "segment". Thus, Applicants respectfully request withdrawal of the rejection.

The Examiner objected to the recitation "14" in claim 29. Claim 29 depends from claim 28 which refers to "14" only once in the phrase "amino acid positions 14 ...". Thus, it is clear that the recitation of "14" in claim 29 refers to amino acid position 14 as defined in claim 28.

Accordingly, it is believed that the claims fully comply with § 112, second paragraph, and withdrawal of this rejection is respectfully requested.

Rejection of Claims Under Section 102(b)

The Examiner rejected claim 1 under 35 U.S.C. § 102(b) as anticipated by Foster et al. Claim 1 has been cancelled rendering this rejection moot. Applicants respectfully request withdrawal of the rejection.

Rejection of Claims Under Section 103(a)

The Examiner rejected claims 1-4 and 10-13 under 35 U.S.C. § 103(a) as obvious over Foster et al. in view of Ashkenazi et al. Applicants respectfully traverse the rejection.

"To establish a *prima facie* case of obviousness, three basic criteria must be met. First, there must be some suggestion or motivation, either in the references themselves or in the knowledge generally available to one of ordinary skill in the art, to modify the reference or to combine reference teachings. Second, there must be a reasonable expectation of success. Finally, the prior art reference (or references when combined) must teach or suggest all the claim limitations." M.P.E.P. §2143 at 2100-97. Applicant submits that the basic criteria are not met because 1) the prior art references do not teach all the claimed limitations of the present invention and 2) there is no motivation in the references to modify the prior art.

The Foster et al. reference discloses employing a sequence from t-PA to provide for secretion of thrombopoietin. The Foster et al. reference does not discuss secretion of immunoadhesins or that a sequence including a pro-sequence of a mammalian t-PA could provide for secretion of an immunoadhesin. With respect to claims 10-13, the Foster et al. reference also does not discuss operably linking a mammalian t-PA pro-sequence with a pre-sequence other than a mammalian t-PA pre-sequence.

The deficiencies of the Foster et al reference are not remedied by reference to the Ashkenazi et al. reference. Ashkenazi et al. disclose that TNFR-IgG is useful to protect against endotoxin shock. The article discloses that the recombinant TNFR-IgG is secreted and recovered from the cell culture medium. The reference does not discuss or suggest that secretion of the TNFR-IgG is problematic or needs to be increased, or that such an increase in secretion can be accomplished by using a sequence including a mammalian t-PA pro-sequence. The Ashkenazi et al. reference also does not discuss operably linking a mammalian t-PA pro-sequence with a pre-sequence other than a mammalian t-PA pre-sequence.

Thus, the Foster et al. reference and the Ashkenazi et al. reference in combination do not disclose all of the elements of the claimed invention. In addition, there would be no motivation to combine these references because neither reference discusses secretion of immunoadhesins nor the need to change the level of secretion of an immunoadhesin. Thus, Applicants respectfully request withdrawal of the rejection.

The Examiner rejected claims 1-13 as unpatentable over Foster et al. in view of Ashkenazi et al. and Rickles et al. Applicants respectfully traverse the rejection.

The Foster et al. reference and Ashkenazi et al. references have been discussed above and the same arguments apply to this rejection.

The deficiencies of the Foster and Ashkenazi et al. references are not remedied by reference to Rickles et al. The Rickles et al. reference is directed to isolation and purification of a cDNA encoding a murine tissue plasminogen activator for use as a probe to analyze t-PA gene expression during F9 cell differentiation. There is no discussion or suggestion in this reference that a sequence including a pro-sequence of a mammalian t-PA can or should be used to provide for secretion of any protein much less an immunoadhesin. Moreover, there is no discussion or suggestion that the pro-sequence of a mammalian t-PA sequence be operably

linked to a pre-sequence other than a mammalian t-PA pre-sequence. Thus, Applicants respectfully request withdrawal of the rejection on this basis.

The Examiner rejected claims 1-4, 10-14, 16-22 and 23-33 as being unpatentable over Foster et al in view of Ashkenazi et al. and Berman and Lasky et al. Applicants respectfully traverse the rejection.

The Foster et al. and Ashkenazi et al. references are discussed above and the same arguments apply with respect to this rejection.

The deficiencies of these references are not remedied by reference to the Berman and Lasky et al. reference. The Berman and Lasky et al. reference is a general reference that discusses the advantages of expression of fully glycosylated glycoproteins in mammalian cells, in particular, the expression of viral glycoproteins. There is no discussion in this very general reference of problems with secretion of glycoproteins nor that a sequence including a pro-sequence of a mammalian t-PA be operably linked to a DNA segment encoding an immunoadhesin or operably linked to a pre-sequence other than a mammalian t-PA pre-sequence. Furthermore, this reference does not teach or suggest the formation of glycosylation site variants. One of skill in the art reading the reference would not be motivated to prepare glycosylation site variants because the reference teaches the advantage of fully glycosylated glycoproteins. Thus, Applicants respectfully request withdrawal of the rejection.

In light of the foregoing amendments and remarks, it is believed that the application is in condition for allowance. A notification to that effect is earnestly solicited. The Examiner is invited to telephone Applicants' undersigned representative at the telephone number listed below if the Examiner believes that doing so will advance prosecution of this application.



Date: February 28, 2001

Respectfully submitted,

Ashkenazi et al., by their attorneys

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Katherine M. Kowalchuk
Katherine M. Kowalchuk
Reg. No. 36,848
KMK:cna

***MARKED VERSION OF THE SPECIFICATION
SHOWING MOVEMENT OF TEXT***

PROTEIN SECRETION
Background of the Invention

Field of the Invention

The present invention relates generally to the field of protein production by cell culture. In particular aspects, the invention provides methods and compositions for the production of polypeptides, especially by eukaryotic cell culture, which enhance secretion and facilitate recovery of the polypeptides.

Description of Related Disclosures

Many eukaryotic cell surface- and secreted proteins are post-translationally processed to incorporate N-linked and O-linked carbohydrate (Kornfeld and Kornfeld (1985) *Annu. Rev. Biochem.* 54:631-64; Rademacher *et al.*, (1988) *Annu. Rev. Biochem.* 57:785-838). Protein glycosylation is thought to subserve a variety of functions including: augmentation of protein folding, inhibition of protein aggregation, regulation of intracellular trafficking to organelles, increasing resistance to proteolysis, modulation of protein antigenicity, and mediation of intercellular adhesion (Fieldler and Simons (1995) *Cell* 81:309-312; Helenius (1994) *Mol. Biol. of the Cell* 5:253-265; Olden *et al.*, (1978) *Cell*, 13:461-473; Caton *et al.*, (1982) *Cell* 37:417-427; Alexander and Elder (1984) *Science* 226:1328-1330; Flack *et al.*, (1994) *J. Biol. Chem.* 269:14015-14020). In higher organisms, the nature and extent of glycosylation can markedly affect the circulating half-life and bioavailability of secreted proteins by mechanisms involving receptor mediated uptake and clearance (Ashwell and Morrell (1974) *Adv. Enzymol.* 41:99-128; Ashwell and Harford (1982) *Ann. Rev. Biochem.* 51:531-54). Receptor systems have been identified that are thought to play a major role in the clearance of serum proteins through recognition of various carbohydrate structures on the glycoproteins (Stockert (1995) *Physiol. Rev.* 75:591-609; Kery *et al.*, (1992) *Arch. Biochem. Biophys.* 298:49-55). Thus, production strategies resulting in incomplete attachment of terminal sialic acid residues might provide a means of shortening the bioavailability and half-life of secreted glycoproteins by promoting clearance by the hepatic asialoglycoprotein receptor. Conversely, expression strategies resulting in saturation of terminal sialic acid attachment sites might lengthen protein bioavailability and half-life by preventing uptake by hepatic receptors. In the development of recombinant glycoproteins for use as pharmaceutical products, it has been speculated that the pharmacodynamics of recombinant proteins can be modulated by the addition or deletion of glycosylation sites from a glycoprotein's primary structure (Berman and Lasky (1985a) *Trends in Biotechnol.* 3:51-53). However, studies have reported that the deletion of N-linked glycosylation sites often impairs intracellular transport and results in the intracellular accumulation of glycosylation site variants (Machamer and Rose (1988) *J. Biol. Chem.* 263:5955-5960; Gallagher *et al.*, (1992) *J. Virology* 66:7136-7145; Collier *et al.*, (1993) *Biochemistry* 32: 7818-7823; Claffey *et al.*, (1995) *Biochimica et Biophysica Acta* 1246 :1-9; Dube *et al.*, (1988) *J. Biol. Chem.* 263:17516-17521). While glycosylation site variants of secreted proteins can be expressed intracellularly, it has proved difficult to recover useful quantities from growth conditioned cell culture medium.

It has been shown that impaired secretion of the HIV-1 envelope glycoprotein containing N-linked carbohydrate structures can be partially overcome by replacing the native signal sequence of the glycoprotein with the signal sequence and 5' untranslated region of the herpes simplex virus type 1 glycoprotein D (HSV gD-1) (Lasky *et al.*, (1986) *Science* 233:209-212; Berman *et al.*, (1989) *J. Virol.* 63:3489-3498). Studies

-1- 1 Text moved from page 1
(1) to page 2 of substitute
specification

have reported the use of the native secretory peptide of human tissue type plasminogen activator in cell culture production of non-t glycoproteins (International Publication No. W 6/17067; Krasney and Young (1992) Cytokine 4:134-143; Rhodes *et al.*, (1994) J. Gen. Virol. 75:207-213). None have reported a strategy for the secretion and recovery of proteins wherein one or more native glycosylation sites have been added to or deleted from the protein's primary structure.

Summary of the Invention

The present invention provides methods and compositions useful in the production of proteins by recombinant cell culture. The methods and compositions overcome intracellular retention of proteins and facilitate extracellular recovery of the produced proteins. In particular embodiments, the invention provides methods and compositions for the production of polypeptides other than tissue-type plasminogen activators (t-PA's) utilizing a precursor peptide corresponding to the amino terminal signal and/or pro peptides naturally associated with a mammalian t-PA which act to direct the secretion of the mature t-PA. In particular embodiments, the invention provides for the export and secretion of polypeptides other than t-PA's. For example, the invention provides methods and compositions useful in the recombinant production and extracellular recovery of novel chimeric or fusion proteins such as immunoadhesins and especially those with poor secretion kinetics. In particular embodiments the invention provides for the production and recovery of glycoproteins that have been altered from their native sequence to add or remove one or more glycosylation sites. Advantageously, the invention improves and in preferred embodiments restores the export and secretion of such glycosylation site variants. It is a further advantage of the present invention that greater quantities of the polypeptides produced utilizing the compositions and methods of the present invention can be recovered from the extracellular medium of the cultured cells from which they are produced.

Accordingly, in particular embodiments, the invention provides nucleic acids, expression systems and host cells, as well as methods for the production of non t-PA polypeptides, such as immunoadhesins and especially glycosylation site variant polypeptides, in cell culture. In one embodiment of the present invention, a DNA construct is provided for the export and secretion of such polypeptides comprising a first DNA segment encoding a precursor peptide corresponding to all or a portion of the amino terminal signal and/or pro peptides naturally associated with a mammalian and preferably a human t-PA. The first DNA segment is operably linked, in frame, to a second DNA segment encoding the heterologous (non-t-PA) polypeptide. In particular aspects, the first DNA segment encodes a peptide corresponding to a mammalian and preferably a human t-PA pro-sequence as defined herein. According to this aspect of the present invention, the first DNA segment is operably linked to a second DNA segment encoding a heterologous polypeptide.

Certain embodiments additionally comprise a DNA segment encoding a peptide corresponding to a mammalian signal and or pro-peptide upstream of and operably linked to the first DNA segment. For example, when the heterologous polypeptide is an immunoadhesin, such as a TNFR-IgG chimera, the first DNA segment may be preceded by a DNA segment encoding a mammalian t-PA or, alternatively, a heterologous signal and or pro-sequence. According to this aspect of the invention the mammalian t-PA signal sequence or other heterologous signal and or pro-sequence and the pro-peptide amino acid sequence comprise the precursor peptide of the invention.

In preferred embodiments, the first DNA segment encodes a native or naturally occurring signal and pro peptide of a mammalian t-PA and especially a human t-PA. The second DNA sequence preferably encodes a polypeptide other than a mammalian t-PA such as, for example, an immunoadhesin. According to further

-2- 1 text moved from page 2
of the original
(1) specification to
page 3 of the substitute
specification

aspects of the invention, the second DNA sequence encodes a naturally occurring or chimeric polypeptide other than a mammalian A wherein one or more glycosylation sites have been added to or deleted from the polypeptide's native sequence. The invention further provides a DNA construct comprising one or more additional DNA segments operably linked to the first and second DNA segments.

5 The invention further provides a cultured eukaryotic host cell comprising a DNA construct having a first DNA segment encoding a precursor peptide the precursor peptide corresponding to all or a portion of a mammalian t-PA signal and or pro peptide and a second DNA segment operably linked to the first DNA sequence, the second DNA sequence encoding a polypeptide other than a mammalian t-PA and preferably a polypeptide other than a mammalian t-PA wherein one or more glycosylation sites have been added to or
10 deleted from the polypeptide. (1)

The invention further provides methods of producing a heterologous polypeptide especially a polypeptide which has been altered to delete one or more native N-linked glycosylation sites comprising the steps of

- (a) culturing a eukaryotic host cell comprising a DNA construct, the DNA construct comprising:
- 15 a first DNA segment encoding a precursor peptide corresponding to all or a portion of a mammalian tissue plasminogen activator signal and or pro peptide; and
- a second DNA segment operably linked to the first DNA sequence, the second DNA sequence encoding a polypeptide other than t-PA wherein one or more native N-linked glycosylation sites of the polypeptide have been deleted from the polypeptide wherein the eukaryotic host cell expresses the first and
20 second DNA segments and the polypeptide is secreted from the cell; and
- (b) recovering the polypeptide so produced.

Brief Description of the Drawings

Figure 1. Diagram of a tumor necrosis factor immunoglobulin chimeric molecule (TNFR-IgG1) and signal sequences. TNFR-IgG1 is a chimeric protein consisting of the extracellular domain of the p55 TNF receptor fused to the hinge and Fc domain of an immunoglobulin heavy chain. TNFR-IgG1 is secreted as a
25 homodimer with four N-linked glycosylation sites (squares) per monomer. The proteins expressed in this study were synthesized using the wild type TNFR signal sequence containing 29 amino acids (SEQ ID NO: 2), or a combination of the TNFR signal sequence and the signal and/or pro-sequence of human tissue plasminogen activator (tPA) (SEQ ID NO: 1).

30 Figures 2A-2D. Effect of the signal sequence on the secretion kinetics of TNFR-IgG1 and tPA.TNFR-IgG1. Parallel cultures of human embryonic kidney cells were transfected with plasmids encoding either TNFR-IgG1 utilizing the native signal sequence or the signal and pro-sequence of t-PA (tPA.TNFR-IgG1) for pulse labeling experiments. Two days post-transfection the culture, medium was removed and replaced (after washing two times) with methionine- and cysteine-free DMEM supplemented with (³⁵S)-labeled methionine
35 and cysteine. Cells were labeled at 37°C (5% CO₂) for the times indicated. The labeling reaction was terminated by washing the cells immediately in chilled (4°C) PBS followed by detergent extraction. Cell lysates and cell culture supernatants were precipitated by the addition of Protein A SEPHAROSE™. The Protein A:TNFR-IgG1 complexes were pelleted by centrifugation, washed repeatedly and eluted in SDS-PAGE sample buffer containing mercaptoethanol. The eluted protein was resolved on 10% SDS-PAGE gels and
40 visualized by autoradiography. Figure 2A, intracellular (i.e. cell associated) TNFR-IgG1; Figure 2B, Secreted TNFR-IgG1; Figure 2C, intracellular tPA.TNFR.IgG; Figure 2D, secreted tPA.TNFR.IgG. }

(1)
Text moved from page 3
of the original specification
to page 4 of the substitute specification

-3-

(2)
Text moved from
page 3 of the original
specification to
page 5 of the
substitute specification

(1)

Figures 3A-3F. Secretion kinetics of TNFR-IgG1 signal sequence and glycosylation mutants. Plasmids encoding fully glycosylated (Figure 3A) or mutated form TNFR-IgG1 (Figures 3B-3F) were transfected into 293 cells and analyzed by pulse-chase analysis as described in Figure 2. Autoradiographs were analyzed with a scanning densitometer and the optical density values for supernatants (○) and cell lysates (■) were normalized and plotted as a function of time (0-24 hr). The glycosylation site mutants are identified using the single letter amino acid code with reference to the amino acid residue present at each of the four N-linked glycosylation sites (amino acid positions 14, 105, 111, and 248). Thus, the designation NNNN represents the wild type TNFR-IgG1, whereas NQNN indicates TNFR-IgG1 where glutamine replaced asparagine at the second glycosylation site (position 105). Figure 3A, TNFR-IgG1; Figure 3B, tPA.TNFR-IgG1; Figure 3C, TNFR-IgG1 mutant lacking 2 native glycosylation sites (NNQQ); Figure 3D, tPA.NNQQ; Figure 3E, QSNQ; Figure 3F, tPA.QSNQ.

Figures 4A-4C. Immunoprecipitation of TNFR-IgG1 glycosylation mutants. Plasmids encoding either TNFR-IgG1 or TNFR-IgG glycosylation site mutants were transfected into 293 cells using calcium phosphate precipitated DNA. Two days post-transfection the culture, medium was removed and replaced (after washing two times) with methionine- and cysteine-free DMEM supplemented with (³⁵S)-labeled methionine and cysteine. Cells were labeled overnight at 37°C (5% CO₂). Cell lysates and cell culture supernatants were precipitated by the addition of Protein A SEPHAROSE™. The Protein A:TNFR-IgG1 complexes were pelleted by centrifugation, washed repeatedly and eluted in SDS-PAGE sample buffer containing mercaptoethanol. The eluted protein was resolved on 10% SDS-PAGE gels and visualized by autoradiography. The glycosylation site mutants were examined in four separate experiments (Figures 4A-4D) where transiently expressed TNFR-IgG1 (TNFR-IgG1) expressed in 293 cells or a stable CHO cell line expressing TNFR-IgG (TRY+) were used as positive controls. Background binding was determined in experiments with cells transfected with thrombopoietin (TPO-). The mobilities of molecular weight markers are indicated at the left margins.

Figures 5A and 5B. Effect of signal sequence replacement on the secretion of TNFR-IgG1 glycosylation site mutants. Plasmids encoding TNFR-IgG1 glycosylation site mutants containing the tPA signal/pro sequence (tPA) (SEQ ID NO: 1) or the TNFR signal sequence (TNFR) (SEQ ID NO: 2) were transfected into 293 cells, metabolically labeled with (³⁵S) methionine and cysteine, and immunoprecipitated from cell culture supernatants (S) or cell lysates (L) by the addition of Protein A SEPHAROSE™ as described in Figure 4. The Protein A:TNFR-IgG1 complexes were pelleted by centrifugation, resolved by SDS-PAGE, and visualized by autoradiography. The mobilities of molecular weight markers are indicated at the left margins.

Figure 6. Characterization of TNFR-IgG1 glycosylation mutants purified for receptor binding studies. TNFR-IgG1 glycosylation site mutants were purified by protein A affinity chromatography from growth conditioned cell culture supernatants of stable transfected CHO cells. The purified proteins were treated with SDS-PAGE sample buffer with- (lanes 8-12) or without (lanes 3-6) added 2-mercaptoethanol and resolved by SDS-PAGE. The resulting gel was stained with Coomassie blue. Each lane contained 3 ug of purified protein. Lanes 3 and 8 contained fully glycosylated TNFR-IgG1; lanes 4 and 9 contained the NNQQ glycosylation site mutant; lanes 5 and 10 contained the NSNQ glycosylation site mutant; lanes 6 and 11 contained the QSNQ glycosylation site mutant. Lane 1 contained molecular weight standards (indicated at left margin), lanes 2, 7, and 12 contained sample buffer alone.

(1)

1 text moved from the original specification at page 4 to page 5 of the substitute specification

(2)

4.

1 text moved from page 4 of the original specification to page 6 of the substitute specification

(1) Figures 7A-7D. Competitive binding of (¹²⁵I)-labeled TNF to TNFR-IgG1 glycosylation mutants. Purified TNFR-IgC and TNFR-IgG1 glycosylation site mutants were captured onto micotiter plates coated with affinity purified goat antibodies to human IgG Fc domain. The captured receptor chimeras were reacted with (¹²⁵I)-labeled TNF along with varying concentrations of unlabeled TNF. The binding of TNF to fully glycosylated TNFR-IgG1 is shown in Figure 7A; binding to the NNQQ glycosylation mutant is shown in Figure 7B; binding to the NSNQ glycosylation mutant is shown in Figure 7C; and binding to the QSNQ glycosylation mutant is shown in Figure 7D.

Figure 8A-C. Secretion kinetics of TNFR-IgG1 signal sequence variants. Plasmids encoding TNFR1-IgG1 utilizing the signal sequence of TNFR1 (SEQ ID NO: 2)(Figure 8A), the signal-pro sequence of tPA (SEQ ID NO: 1)(Figure 8B) or the signal sequence of TNFR1 (SEQ ID NO: 2) and a pro-sequence (SEQ ID NO: 7) of human t-PA (SEQ ID NO: 8) (Figure 8C) were transfected into CHO cells and analyzed by pulse-chase analysis as described in Figure 2. Autoradiographs were analyzed with a scanning densitometer and the optical density values for supernatants (□) and cell lysates (◇) were normalized and plotted as a function of time (0-24 hr).

Detailed Description of the Preferred Embodiments

Definitions

The terms "DNA sequence encoding", "DNA encoding" and "nucleic acid encoding" refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of amino acids along the polypeptide chain. The DNA sequence thus codes for a particular amino acid sequence of a polypeptide.

The terms "t-PA" and "tissue plasminogen activator" refer to a naturally occurring extrinsic (tissue-type) plasminogen activator having fibrinolytic activity and typically having a structure with five domains (finger, growth factor, kringle-1, kringle-2, and protease domains). Naturally occurring mammalian t-PA includes human species as well as other animal species such as rabbit, rat, porcine, non human primate, equine, murine, and ovine t-PA. Nucleic acids encoding t-PA from human and non-human species is known in the art. For example, human t-PA is encoded by the cDNA sequence reported in U.S. Patent Number 4,766,075, issued 23 August 1988.

A "precursor peptide" as used in the context of the present invention and as more fully described herein below, is used to refer to a polypeptide having an amino acid sequence corresponding to all or a portion of a naturally occurring mammalian t-PA signal and/or pro peptide which participates in the secretion of t-PA under native conditions.

"Pre-pro" or "signal-pro" peptide as used in the context of the present invention is meant to refer to an amino acid sequence such as that naturally associated with a mammalian t-PA which acts to direct the secretion of a mature polypeptide, for example, a mammalian t-PA, from a cell. As used herein, the term "signal-pro peptide" includes the "pre-" or "signal" sequence such as that naturally associated with a mammalian t-PA which functions to bind to the signal-recognition particle and direct the protein to the lumen of the endoplasmic reticulum (ER). A "signal" sequence is an amino acid sequence, characteristically hydrophobic in nature, cleaved by signal peptidases in the ER. For example, the signal sequence of t-PA is generally removed from the nascent t-PA co-translationally. In addition to a signal sequence, some mammalian proteins are associated post-translationally with a "pro" sequence such as the signal-pro sequence of a mammalian t-PA. The "pro-" sequence serves to target the nascent polypeptide, for example a mature t-PA,

(1)
text moved from
the original specification at
page 5 to substitute specification
at page 61

-5-

(2)
text moved from page
5 of the original
specification to page 7
of the substitute
specification

(1) to the Golgi apparatus (GA) and is cleaved post-translationally. The pro-sequence is characteristically positively charged. commonly contains golgi peptidase cleavage sequences.

The amino acid sequences of the mammalian t-PA signal-pro peptides are generally known or obtainable through conventional techniques. Signal-pro peptides from human and non-human t-PAs are known in the art and have been disclosed in, for example U.S. Patent 4,766,075; Rickles *et al.*, (1988) J. Biol. Chem. 263:1563-1560 and Feng *et al.*, (1990) J. Biol. Chem. 265:2022-2027. The term native signal-pro peptide specifically encompasses naturally-occurring pre- and prepro- sequences as defined and includes naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the t-PA signal-pro peptide. DNA sequences encoding mammalian t-PA amino terminal signal-pro peptides can be cloned as cDNA or genomic molecules according to techniques that are standard in the art or can be synthesized, preferably using automated equipment and the application of conventional synthetic protocols.

As used herein, "heterologous polypeptide" refers generally to polypeptides and proteins regardless of their origin other than a t-PA or a variant thereof and generally having more than about ten amino acids which may or may not have one or more native or synthetic sites for the attachment of a carbohydrate.

Preferably, heterologous polypeptides are "heterologous glycoproteins", that is a heterologous polypeptide as described above having one or more sites for the attachment of a carbohydrate in their native sequence.

Examples of heterologous glycoproteins include molecules such as cytokines and their receptors, as well as chimeric proteins comprising cytokines or their receptors, including, for instance tumor necrosis factor alpha and beta, their receptors (TNFR-1; Gray *et al.*, (1990) Proc. Natl. Acad. Sci. USA 87:7380-7384; and TNFR-

2; Kohno *et al.*, (1990) Proc. Natl. Acad. Sci. USA 87:8331-8335) and their derivatives; renin; a growth hormone, including human growth hormone, and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha-1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIc, factor IX, tissue factor, and von Willebrands factor; anti-clotting factors such as Protein

C; atrial natriuretic factor; lung surfactant; a plasminogen activator other than a tissue-type plasminogen activator (t-PA), for example a urokinase; bombesin; thrombin; hemopoietic growth factor; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP-1-alpha); a serum albumin such as human serum albumin; mullerian-inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse gonadotropin-associated peptide; a microbial protein, such as beta-

lactamase; DNase; inhibin; activin; vascular endothelial growth factor (VEGF); receptors for hormones or growth factors; integrin; protein A or D; rheumatoid factors; a neurotrophic factor such as bone-derived neurotrophic factor (BDNF), neurotrophin-3, -4, -5, or -6 (NT-3, NT-4, NT-5, or NT-6), or a nerve growth factor such as NGF- β ; platelet-derived growth factor (PDGF); fibroblast growth factor such as aFGF and bFGF; epidermal growth factor (EGF); transforming growth factor (TGF) such as TGF-alpha and TGF-beta,

including TGF- β 1, TGF- β 2, TGF- β 3, TGF- β 4, or TGF- β 5; insulin-like growth factor-I and -II (IGF-I and IGF-II); des(1-3)-IGF-I (brain IGF-I), insulin-like growth factor binding proteins; CD proteins such as CD-3, CD-4, CD-8, and CD-19; erythropoietin; osteoinductive factors; immunotoxins; a bone morphogenetic protein (BMP); an interferon such as interferon-alpha, -beta, and -gamma; colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF; interleukins (ILs), e.g., IL-1 to IL-10; superoxide dismutase; T-cell receptors;

surface membrane proteins; decay accelerating factor; viral antigen such as, for example, a portion of the HIV-1

(1)
§ 1 text moved from page 6 of the original specification to page 7 of the substitute specification

(2)
1 text moved from page 6 of the original specification to page 8 of the substitute specification

(3)
§ 3 text moved from page 6 of the original specification to page 9 of the substitute specification

(1)

envelope glycoprotein, gp120, gp160 or fragments thereof; transport proteins; homing receptors; addressins; regulatory proteins, antibodies and chimeric proteins, such as immunohesins.

Preferably the heterologous glycoproteins are "glycosylation site variants" of any of the heterologous glycoproteins described above. More particularly, the glycosylation site variants according to the present invention are naturally occurring heterologous glycoproteins or variations thereof such as the chimeric proteins described above, having at least one site for glycosylation, preferably an N-linked glycosylation site, that has been added to or deleted from their native sequence. Such glycosylation site variants include both "glycosylation site addition variants" as well as "glycosylation site deletion variants" so named herein to delineate heterologous glycoproteins as defined above having one or more sites for glycosylation, preferably N-linked, added to or deleted from their native sequence, respectively.

The heterologous glycoproteins of the present invention have one or more carbohydrate structures that occur on the native protein expressed as N-linked or O-linked carbohydrates. The N-linked and O-linked carbohydrates differ primarily in their core structures. N-linked glycosylation refers to the attachment of the carbohydrate moiety via N-acetylglucosamine (GlcNAc) to an asparagine residue in the peptide chain. The amino acid sequence of the heterologous polypeptide will contain an asparagine-X-serine, asparagine-X-threonine, or asparagine-X-cysteine, wherein X is any amino acid except proline. O-linked carbohydrates, by contrast are characterized by a common core structure, which is the N-acetylgalactosamine (GalNAc) attached to the hydroxyl group of a threonine or serine in the native amino acid sequence of the heterologous polypeptide.

The terms "tumor necrosis factor receptor" and "TNFR" in the context of the present invention refer to a polypeptide comprising the amino acid sequence of a native TNF binding polypeptide, or any combination, derivative or fragment thereof which is capable of binding to tumor necrosis factor- α and/or - β (TNF- α and/or - β). This definition includes substantially intact cell surface or soluble type 1 and type 2 TNFR polypeptides (TNFR1 and TNFR2) from natural sources, synthetically produced *in vitro* or obtained by genetic manipulation including methods of recombinant DNA technology, as well as various chain combinations of such polypeptides. Native TNFR include human and non-human animal, e.g. murine, bovine, equine, porcine, etc. TNFR polypeptides. The non-human mammalian species can, for example, be obtained by cross-species hybridization, using probes obtained from the human DNA sequence as hybridization probes to isolate TNFR cDNAs from the respective non-human mammalian cDNA libraries.

The chimeric gene encoding TNFR1-IgG1 is described in Ashkenazi *et al.*, (1991) Proc. Natl. Acad. Sci. 88:10535-10539. TNFR1-IgG1 is a chimeric protein constructed by fusing the extracellular domain of the receptor type 1 for TNF alpha with sequences encoding the Fc domain and hinge region of IgG1 (Ashkenazi *et al.*, (1991). The chimeric protein (Figure 1) contains four N-linked glycosylation sites: three located in the TNFR region (positions 14, 105, and 111) and one in the Fc domain (position 248). For simplicity, the glycosylation mutants described in this invention are named using the single letter amino acid code with reference to the amino acid residue present at each of the four N-linked glycosylation sites at amino acid positions 14, 105, 111, and 248 (Figure 1). Thus, the designation NNNN represents the fully glycosylated TNFR1-IgG1, whereas NQNN indicates TNFR-IgG1 where glutamine replaced asparagine at the second glycosylation site (position 105).

As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the "binding domain" of a heterologous protein (an "adhesin", e.g. a receptor, ligand or enzyme) with the effector

(2)

(1)
text moved from page 7 of the original specification to page 9 of the substitute specification

-7-

(2)
text moved from page 9 of the original specification to page 10 of the substitute specification

(1) functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of the adhesin amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site (antigen combining site) of an antibody (i.e. is "heterologous") and an immunoglobulin constant domain sequence. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG₁, IgG₂, IgG₃, or IgG₄ subtypes, IgA, IgE, IgD or IgM. Immunoadhesins are described in, for example, U.S. Patent Nos. 5,116,964, 5,714,147 and 5,336,603 the disclosures of which are hereby incorporated by reference. Immunoadhesins include CD4 (Capon *et al.*, (1989) Nature 337:525-531; Traunecker *et al.*, (1989) Nature 339:68-70; and Byrn *et al.*, (1990) Nature 344:667-670); L-selectin or homing receptor (Watson *et al.*, (1990) J. Cell. Biol. 110:2221-2229; and Watson *et al.*, (1991) Nature 349:164-167); CD44 (Aruffo *et al.*, (1990) Cell 61:1303-1313; CD28 and B7 (Linsley *et al.*, (1991) J. Exp. Med. 173:721-730); CTLA-4 (Lisley *et al.*, J. Exp. Med. 174:561-569); CD22 (Stamenkovic *et al.*, Cell 66:1133-1144); TNF receptor (Ashkenazi *et al.*, (1991) Proc. Natl. Acad. Sci. USA 88:10535-10539; Lesslauer *et al.*, (1991) Eur. J. Immunol. 27:2883-2886; and Peppel *et al.*, (1991) J. Exp. Med. 174:1483-1489; Mohler *et al.*, (1993) J. Immunol. 151:1548-1561); NP receptors (Bennett *et al.*, (1991) J. Biol. Chem. 266:23060-23067; interferon γ receptor (Kurschner *et al.*, (1992) J. Biol. Chem. 267:9354-9360; 4-1BB (Chalupny *et al.*, (1992) PNAS USA 89:10360-10364) and IgE receptor α (Ridgway and Gorman, (1991) J. Cell. Biol. 115, Abstract No. 1448).

The terms "host cell" and "host cell line" refer to cells and cell lines derived from a prokaryotic or eukaryotic organism that are capable of growth and survival when placed in either monolayer culture or in suspension culture in a medium containing the appropriate nutrients and growth factors. Suitable host cells for use within the present invention include any type of cell that can be engineered to express a DNA molecule, can be grown in culture, and have a secretory pathway. Although prokaryotic cells such as E. coli cells are capable of secreting protein at least into the periplasmic space, it is preferred within the context of the present invention to use cultured eukaryotic cells, such as fungal cells, insect cells, yeast cells or in particular mammalian cells. The necessary growth factors for a particular cell line are readily determined empirically without undue experimentation, as described for example in Mammalian Cell Culture (Mather, J.P. ed., Plenum Press, N.Y. [1984]), and Barnes and Sato, (1980) Cell, 22:649. Typically, the cells are capable of expressing and secreting large quantities of a particular glycoprotein of interest into the culture medium. Examples of such cells include SF9 insect cells (Summers and Smith (1987) Texas Agriculture Experiment Station Bulletin, 1555; and Insect Cell Culture Engineering, Goosen Daugulis and Faulkner Eds. Dekker, New York). Examples of suitable mammalian host cells within the context of the present invention may include Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 [1980]); dp12.CHO cells (EP 307,247 published 15 March 1989); monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham *et al.*, J. Gen Virol., 36:59 [1977]); baby hamster kidney cells (BHK, ATCC CCL 10); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 [1980]); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB³8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather *et al.*, Annals N.Y. Acad. Sci., 383:44-68 [1982]); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).

(1)
text moved from page 8 of the original specification to page 10 of substitute specification

(2)
text moved from page 8 of the original specification to page 11 of the substitute specification

(3)
text moved from page 8 of the original specification to page 12 of substitute specification

Preferred host cells include Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 7: 16 [1980]); dp12.CHO cells (EP 307,247 published 15 March 1989).

(1) "Expression vector" refers to a DNA construct containing a DNA sequence which is operably linked to a suitable control sequence capable of effecting the expression of the DNA in a suitable host. Such control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, optional RNA splice donor/acceptor sequences, a sequence encoding suitable mRNA ribosome binding sites, and sequences which control termination of transcription and translation. The vector may be a plasmid, a phage particle, a recombinant virus or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself. In the present specification, "plasmid" and "vector" are sometimes used interchangeably as the plasmid is the most commonly used form of vector at present. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which are, or become, known in the art.

"Operably linked" when describing the relationship between two DNA regions simply means that they are functionally related to each other. For example, a signal sequence is operably linked to a peptide if it functions to ensure synthesis on membrane bound ribosomes and to translocate the nascent protein across the lumen of the endoplasmic reticulum as a signal sequence, participating in the secretion of the mature form of the protein most probably involving cleavage of the signal sequence. A promoter is operably linked to a coding sequence if it controls the transcription of the sequence; a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation. Therefore, nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

The terms "transfected," "transformed (host) cell", "transfectant" and "transformed" and the like refer to the introduction of DNA into a cell. The cell is termed a "host cell". The introduced DNA is usually in the form of a plasmid derived vector containing an inserted piece of DNA. The introduced DNA sequence may be from the same species as the host cell or a different species from the host cell, or it may be a hybrid DNA sequence, containing some foreign and some homologous DNA. The words transformants and transformed (host) cells include the primary subject cell and cultures derived therefrom, without regard to the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations or amplification of chromosomal fragments. Mutant progeny that have the same function or biological property as screened for in the originally transformed cell are included. The term amino acid or amino acid residue, as used herein, refers to naturally occurring L amino acids or residues, unless otherwise specifically indicated. The commonly used one- and three-letter abbreviations for amino acids are use herein (Lehninger, A. L., *Biochemistry*, 2d ed., pp. 71-92, Worth Publishers, N. Y. (1975)).

Modes for Carrying out the Invention

Studies have demonstrated that deletion of N-linked glycosylation sites from a glycoprotein's primary structure often impairs the intracellular transport and secretion of the polypeptide. According to the present invention, the defect in secretion of such polypeptides can be overcome by operably linking the nucleic acid }

(1)
Text moved from
page 9 of the original specification
to page 12 of the substitute
specification

-9-

(2)
Text moved from
page 9 of the original
specification to page
13 of the substitute
specification

(1) | sequence encoding the polypeptide to a nucleic acid sequence encoding a precursor peptide. Surprisingly, the precursor polypeptide increased the secretion efficiency of the precursor glycoprotein as well. The precursor peptide has an amino acid sequence which corresponds to all or a portion of a naturally occurring mammalian t-PA signal-pro peptide which participates in the secretion of t-PA under native conditions.

5 Preferably the precursor peptide of the present invention is "capable of restoring the export and secretion" of a heterologous polypeptide, especially a heterologous glycoprotein such as an immunoadhesin and more preferably a heterologous glycosylation site variant glycoprotein to the extracellular space. As will be appreciated by the skilled artisan "capable of restoring the export and secretion" of a polypeptide to the extracellular space is a relative term. Thus the term when used to describe the biological activity of the
10 precursor peptide means a peptide that when linked to a heterologous polypeptide produces an increase in the amount of heterologous polypeptide that can be recovered from the extracellular space when compared to the amount recoverable from the extracellular space in the absence of the precursor peptide of the present invention and in the presence of the native signal and/or pro sequence of the heterologous polypeptide. |

To determine whether the precursor peptide improves the export and secretion of the polypeptide, the (2)
15 efficiency of intracellular transport can be measured by routine experimentation. For example, a plasmid can be constructed for transient transfection studies in eukaryotic host cells. Pulse-chase experiments similar to those described herein will show that replacement of the native signal sequence associated with the heterologous polypeptide with the precursor peptide of the present invention results in an improvement in secretion efficiency. Thus, after transient expression at, for example 24 hours, the amount of heterologous
20 polypeptide secreted into the culture medium can be measured and compared to a control using a native or other signal sequence. For example, approximately 70-80% and preferably 80-100% of the pulse-labeled heterologous polypeptide can be secreted into the cell culture medium when a precursor peptide of the present invention is employed in the expression construct, whereas only 50-60% of the heterologous polypeptide is secreted using the wild-type or native signal sequence. This represents a 20 to 50% increase in secretion
25 efficiency.

The increased efficiency of secretion achieved according to the present invention utilizing the precursor peptide is also apparent from the kinetics of secretion of the heterologous polypeptide. For example, when the native signal sequence is employed, 40% of the pulse-labeled heterologous polypeptide is secreted in 2-4 hrs. after pulse labeling. However when the native signal sequence is replaced with the precursor peptide
30 corresponding to a mammalian t-PA signal-pro peptide, approximately 60% of the heterologous polypeptide is secreted in this time frame.

The precursor peptide of the present invention has an amino acid sequence which corresponds to all or a portion of the amino acid sequence of a mammalian t-PA signal-pro peptide including native signal-pro peptides of t-PA having the same amino acid sequence as a signal-pro peptide of a mammalian t-PA sequence
35 derived from nature. Using human t-PA as but an example, the signal-pro peptide precedes the mature t-PA protein sequence and acts to direct export and secretion of the mature protein. The approximately 35 amino acid signal pro-peptide of human t-PA consists of a signal sequence of about 21 (SEQ ID NO: 3) or 22 (SEQ ID NO: 12) amino acid residues, also called a pre-sequence, and an 11 (SEQ ID NO: 4) or 10 (SEQ ID NO: 13) amino acid pro-sequence, including a 3 amino acid exopeptidase cleavage site (see, for example, Figure
40 1 infra; Example 8, infra; and Berg and Grinnell (1991) Biochem. Biophys. Res. Commun. 179:31289-1296). However, it is the ability of the precursor peptide to restore or increase export and secretion of the heterologous

(1)
| text is moved from
page 10 of the original
specification to page
13 of the substitute
specification |

-10-

(2)
| text is moved from
page 10 of the original
specification to page
14 of the substitute
specification |

(1) polypeptide and not the length of the precursor peptide that is important. Therefore, in one embodiment of the invention, the signal-pro peptide of a mammalian t-PA is a native 1. an sequence comprising amino acids (2)
1 to 35 of SEQ ID NO: 1 numbered as shown below and corresponding to amino acids -35 to -1 of Fig. 1.

Therefore, in general the present invention makes use of a precursor peptide having the sequence:
5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Met-Asp-Ala-Met-Lys-Arg-Gly-Leu-Cys-Cys-Val-Leu-Leu-Leu-Cys-Gly-
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
Ala-Val-Phe-Val-Ser-Pro-Ser-Gln-Glu-Ile-His-Ala-Arg-Phe-Arg-Arg-
33 34 35
10 Gly-Ala-Arg (SEQ ID NO: 1).

In another embodiment of the invention, the precursor peptide comprises a human t-PA pro-sequence as, for example, amino acids 22 to 32 (SEQ ID NO: 4) of SEQ ID NO: 1, or amino acids 22-35 (SEQ ID NO: 5) of SEQ ID NO: 1 and more preferably amino acid residues 23-35 of SEQ ID NO: 1 (SEQ ID NO: 7). In another embodiment of the invention, the precursor peptide is a human signal-pro sequence comprising amino acids 1 to 32 (SEQ ID NO: 6) of SEQ ID NO: 1 and preferably amino acid residues 1-35 (SEQ ID NO: 1). Such precursor peptides and the DNA encoding them can be isolated from nature or can be produced by recombinant or synthetic means.

In a further aspect of the present invention the precursor peptides of the present invention are homologous amino acid sequences of mammalian t-PA's signal-pro peptides or homologous amino acid sequences of the sequence of, for example, SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7 including homologous in vitro generated variants having the qualitative biological activity defined above. Homology with respect to the precursor peptides of the present invention is defined as the percentage of amino acid residues in a candidate sequence that are identical with either the amino acid residues in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, the amino acid sequence of a mammalian t-PA or a composite sequence of a human and other mammalian sequence as defined herein after aligning the sequences and introducing gaps if necessary to achieve the maximum identity. No N- or C- terminal extensions or deletions in the candidate sequence shall be construed as reducing identity. For example, N- or C-terminal addition of a signal sequence other than that of a mammalian t-PA to mammalian precursor peptide as defined herein is within the scope of the precursor peptide of the invention. "Composite amino acid" within the present invention refers to an alternate amino acid having the same position in the 35 amino acid residue structure as human t-PA from another mammalian vertebrate species. Therefore, an amino acid substitution referred to as a composite amino acid substitution (3) replaces the identified amino acid with the equivalent or composite amino acid from another mammalian species. A composite sequence is defined as having at least one amino acid from the native human t-PA sequence replaced with a composite amino acid from another mammalian species.

Therefore, the invention contemplates an precursor peptide having at least the qualitative biological activity as defined above and having, for example, at least about 75% amino acid homology with the polypeptide of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4 or the polypeptide of SEQ ID NO: 1 lacking the 3 carboxyl terminal amino acid residues, SEQ ID NO: 6 and/or the 21 amino terminal residues, SEQ ID NO: 5. The precursor peptide amino acid sequence preferably will share at least 80%, more preferably, greater than 85% sequence homology with the sequence of SEQ ID NO: 1 or the sequences lacking the 3 carboxyl terminal

(1)
1 text is moved from
page 11 of the original
specification to page
14 of the substitute specification

(2)
-11-
1 text is moved
from page 11
of the original
to page 15 of the substitute
specification

(3)
3 text is
moved
from p. 11
of the
original
to page 16
of the substitute
specification

(1)

amino acid residues (SEQ ID NO: 6) and/or the 21 amino terminal residues (SEQ ID NO: 5). However, a precursor peptide n. exhibit less than 50% sequence homology with sequence of SEQ ID NO: 1 and still retain the characteristics of the precursor peptide as defined above.

Since the mechanism by which the signal-pro peptide of t-PA overcomes endoplasmic reticulum retention may relate to its complex structure, precursor peptides which comprise a portion of a signal-pro peptide as defined above are also within the scope of the present invention. For example, as noted above, the signal-pro peptide of t-PA is unusual, and contains an approximately 21-22 amino acid pre- or signal sequence and a 10 or 11 amino acid pro-sequence, including a 3 amino acid exopeptidase cleavage site (Figure 1). Previous studies, (Berg and Grinnell (1991) Biochem. Biophys. Res. Commun. 179:1289-1296) have shown that the pre- or signal sequence is cleaved co-translationally in the endoplasmic reticulum and that the pro-sequence is removed in the Golgi apparatus (GA) by cleavage at a furin processing site. The fact that the endo H sensitive, intracellular forms of an exemplary heterologous glycoprotein glycosylation site variant expressed with the amino terminal precursor peptide sequence of the present invention possessed higher molecular weight than the secreted products demonstrates that, like wild type t-PA, removal of the pro-sequence from glycosylation mutants occurs during export through the GA. Based on these observations, the amino terminal pro-sequence of t-PA represents a structural element able to promote ER to GA transport of the heterologous polypeptide, and especially glycosylation mutants.

Therefore according to a preferred aspect of the present invention, a precursor peptide comprising all or a portion of the pro-sequence of a mammalian-tPA is employed to effect the export and secretion of the heterologous polypeptides of the present invention. For example, the pre-sequence of any mammalian pre-protein sequence, for example, that associated with the native heterologous polypeptide, may be employed in conjunction with the pro-sequence of a mammalian t-PA in the precursor peptide of the present invention. For example, insertion of the 13 amino acid tPA pro-peptide Ser-Gln-Glu-Ile-His-Ala-Arg-Phe-Arg-Arg-Gly-Ala-Arg (SEQ ID NO: 7) between the TNFR1-IgG1 endogenous signal sequence, i.e., that naturally associated with TNFR1 (Gray *et al.*, (1990) supra, amino acids -40 to -12 of Figure 1, SEQ ID NO: 2) and the TNFR1-IgG1 coding sequence provides a precursor peptide (SEQ ID NO: 8) within the context of the present invention that exhibits an increase in export and secretion of the mature molecule (TNFR1-IgG1).

(2)

According to another aspect of the present invention the DNA sequence of the t-PA pro-sequence (SEQ ID NO: 5; SEQ ID NO: 7) is modified to introduce or eliminate proteolytic processing sites. Such modified precursor peptides are described in, for example, International publication No. WO 96/17067. Briefly, and while not wishing to be bound by theory it is believed that pro-sequence of mammalian t-PA is cleaved at a site dependent upon a prohormone converting enzyme such as the yeast KEX2 gene product or the mammalian enzymes PC1, PC2 and furin. Enzymes of this type recognize cleavage sites characterized by arginine residues in the -1 and -4 positions. Cleavage is facilitated by a basic amino acid residue e.g. Lys or Arg in the -1 position. Within the present invention therefore are a pro-sequence having an Arg at residue 35 and 32 and optionally a basic amino acid residue at position 34.

As indicated, the present invention further comprises a second DNA segment encoding a heterologous polypeptide, i.e., a polypeptide other than a mammalian t-PA such as a TNFR immunoadhesin. Preferably the heterologous polypeptide lacks or has been modified to delete one or more native glycosylation sites as described. }

(1)

Text is moved from p. 12 of original specification to page 16 of the substitute specification

-12-

(2)

Text is moved from p. 12 of the original specification to page 17 of the substitute specification

(1) Deletion of glycosylation sites from a heterologous polypeptide may be accomplished by altering the amino acid sequence of the polypeptide. The alteration may be made by, for example, the addition of or substitution by one or more amino acids to the polypeptide's native sequence. For example, if N-linked glycosylation is contemplated, the glycosylation site in the variant is a tripeptidyl sequence of the formula: asparagine-X-serine or asparagine-X-threonine, wherein asparagine is the acceptor and X is any of the twenty genetically encoded amino acids except proline. (See Struck, D.K. and Lennarz, W.J. in The Biochemistry of Glycoproteins and Proteoglycans, W.J. Lennarz ed., Plenum Press, 1980, p. 35; Marshall, R.D. (1974) Biochem. Soc. Symp. 40:17; and Winzler, R.J. in Hormonal Proteins and Peptides, Li, C.I. ed., Academic Press, New York, 1973, pp. 1-15). The amino acid sequence variants herein are modified by substituting appropriate amino acid(s) at the proper site(s) to effect a change in the native glycosylation site. For example an asparagine residue can be replaced by a glutamine residue to disrupt a native glycosylation site within the polypeptide.

If O-linked glycosylation is to be employed, O-glycosidic linkage occurs in animal cells between N-acetylgalactosamine, galactose or xylose, and one of several hydroxyamino acids, most commonly serine or threonine, but also in some cases a 5-hydroxyproline or 5-hydroxylysine residue placed in the appropriate region of the molecule.

According to the present invention the polypeptides are altered through changes at the DNA level, particularly by mutating the DNA encoding the polypeptide at preselected bases, i.e., those encoding N- or O-linked glycosylation sites such that codons are generated that will translate into amino acids other than those that will typically be present for N- or O-linked glycosylation. The variations can be made using methods known in the art such as oligonucleotide-mediated (site directed) mutagenesis, alanine scanning and PCR mutagenesis. Site directed mutagenesis (Carter *et al.*, (1986) Nucl. Acids Res. 13:4331; Soller *et al.*, (1987) Nucl. Acids Res., 10:6487, cassette mutagenesis (Wells *et al.*, (1985) Gene 34:315), restriction selection mutagenesis (Wells *et al.*, (1986) Philos. Trans. R. Soc. London) or other known techniques can be performed on the cloned DNA to produce the glycosylation site mutants that are a subject of the present invention.

Therefore, according to the present invention in order to direct the secretion of a heterologous polypeptide and preferably a glycosylation variant as described above, a DNA segment encoding a precursor peptide is joined to a DNA sequence encoding the heterologous polypeptide in the correct reading frame so that the joined sequences encode a fusion protein.

Expression vectors for use in the methods and compositions of the present invention will generally include a promoter capable of directing the transcription of the first and second DNA of the invention. The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers. Preferred promoters include viral promoters and cellular promoters.

Host cells are transfected or transformed with expression or cloning vectors described herein for heterologous polypeptide production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the

(1)
1 text is moved from
original p. 13 to
page 17 of the
substitute specification

(2)
-13-
1 text is moved from
the original p. 13 to
page 18 of the substitute
specification

(3)
2 text is moved
from p. 13
of the original
specification to
p. 19 of the
substitute
specification

(1) productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1995) and Sambrook *et al.*, supra.

Methods of transfection are known to the ordinarily skilled artisan, for example, CaPO_4 and electroporation, as well as the use of commercially available cationic lipid reagents which facilitate transfection. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook *et al.*, supra, or electroporation is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw *et al.*, Gene, 23:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transformations have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen *et al.*, J. Bact., 130:946 (1977) and Hsiao *et al.*, Proc. Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, *e.g.*, polybrene, polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown *et al.*, Methods in Enzymology, 185:527-537 (1990) and Mansour *et al.*, Nature, 336:348-352 (1988).

Suitable host cells for the expression of heterologous polypeptide that retain one or more glycosylation sites are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham *et al.*, J. Gen. Virol., 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art. (2)

Host cells containing DNA constructs of the present invention are then cultured to produce the heterologous protein. The cells are cultured according to standard methods in a culture medium containing the necessary nutrients for growth of cultured mammalian cells.

For the culture of the eukaryotic cells expressing the desired protein and modified as described for the instant invention, numerous culture conditions can be used paying particular attention to the host cell being cultured. Suitable culture conditions for eukaryotic cells are well known in the art (J. Immunol. Methods (1983)56:221-234) or can be easily determined by the skilled artisan (see, for example, Animal Cell Culture: A Practical Approach 2nd Ed., Rickwood, D. and Hames, B.D., eds. Oxford University Press, New York (1992)), and vary according to the particular host cell selected.

The eukaryotic cell culture of the present invention is prepared in a medium suitable for the particular cell being cultured. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium (MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium (DMEM), (Sigma) are exemplary nutrient solutions. In addition, any of the media described in Ham and Wallace, (1979) Meth. Enz., 58:44; Barnes and Sato, (1980) Anal. Biochem., 102:255; U.S. Patent Nos. 4,767,704; 4,657,866; 4,927,762;

(1)
1 text is moved from
p. 14 of the original specification
to page 19 of the substitute
specification 1

(2)
1 text is moved from
p. 14 of the original
specification to
page 20 of the
substitute specification

(1) 5,122,469 or 4,560,655; International Publication Nos. WO 90/03430; and WO 87/00195; the disclosures of all of which are incorporated herein by reference, may be used as culture media. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as Gentamycin™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range) lipids (such as linoleic or other fatty acids) and their suitable carriers, and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.

10 In a particular embodiment, the mammalian host cell is a CHO cell, preferably a DHFR-CHO cell and a suitable medium contains a basal medium component such as a DMEM/HAM F-12 based formulation (for composition of DMEM and HAM F12 media, see culture media formulations in American Type Culture Collection Catalogue of Cell Lines and Hybridomas, Sixth Edition, 1988, pages 346-349) (the formulation of medium as described in U.S. Patent 5,122,469 are particularly appropriate) with modified concentrations of some components such as amino acids, salts, sugar, and vitamins, and optionally containing glycine, hypoxanthine, and thymidine; recombinant human insulin (2), hydrolyzed peptone, such as Primatone HS or Primatone RL (Sheffield, England), or the equivalent; a cell protective agent, such as Pluronic F68 or the equivalent pluronic polyol; Gentamycin; and trace elements.

20 For the production of the sought after glycoproteins, production by growing the host cells of the present invention under a variety of cell culture conditions is typical. For instance, cell culture procedures for the large or small scale production of proteins are potentially useful within the context of the present invention. Procedures including, but not limited to, a fluidized bed bioreactor, hollow fiber bioreactor, roller bottle culture, or stirred tank bioreactor system may be used, in the later two systems, with or without microcarriers, and operated alternatively in a batch, fed-batch, or continuous mode.

25 Following the polypeptide production phase, the polypeptide of interest is recovered from the culture medium using techniques which are well established in the art.

The polypeptide of interest preferably is recovered from the culture medium as a secreted polypeptide. As a first step, the culture medium or lysate is centrifuged to remove particulate cell debris. The polypeptide thereafter is purified from contaminant soluble proteins and polypeptides, with the following procedures being exemplary of suitable purification procedures: by fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; and protein A SEPHAROSE™ columns to remove contaminants such as IgG. A protease inhibitor such as phenyl methyl sulfonyl fluoride (PMSF) also may be useful to inhibit proteolytic degradation during purification.

35 The following examples are offered by way of illustration and not by way of limitation. The disclosures of all citations in the specification are expressly incorporated herein by reference.

EXAMPLES

Introduction

40 The following are general methods used in the Examples that follow. }

(1)
1 text is moved from p.15 of original specification to page 20 of the substitute specification

(2)
-15-
1 text is moved from p.15 of the original specification to page 21 of the substitute specification }

Methods

DNA and instructions. The chimeric gene encoding TNFR-IgG1 is described (Ashkenazi *et al.*, (1991) Proc. Natl. Acad. Sci. 88:10535-10539). Site directed mutagenesis was carried out following the mismatched primer method of Kunkel, *et al.* (1985) Proc. Natl. Acad. Sci. 82:488-492 using the Muta-Gene M13 Kit (Bio-Rad Inc., Hercules, CA). Mutations were verified by dye terminator cycle sequencing using the automated ABI 310 Genetic Analyzer (Applied Biosystems, Foster City, CA). For simplicity, the glycosylation mutants described in this paper are named using the single letter amino acid code with reference to the amino acid residue present at each of the four N-linked glycosylation sites at amino acid positions 14, 105, 111, and 248 (Figure 1). Thus, the designation NNNN represents the fully glycosylated TNFR-IgG1, whereas NQNN indicates TNFR-IgG1 where glutamine replaced asparagine at the second glycosylation site (position 105). TNFR-IgG1 glycosylation variants were cloned into the expression vector pRK5 (Eaton *et al.*, (1986) Biochem. 291:8343-8347), that enabled transient expression in the human embryonic kidney 293 cell line. The pRK5 chimeric transcription unit includes a cytomegalovirus (CMV) immediate early promoter and a simian virus 40 (SV-40) polyadenylation site. For expression in CHO cells, gene encoding TNFR-IgG1 variants were cloned into the closely related expression vector pSVI6B5 that differs from pRK5 in that transcription is directed by SV-40 promoter and enhancer elements rather than by the CMV promoter.

Cells and Transfections. 293 cells were cultured in 100 mm culture plates containing a mixture of Dulbecco's modified Eagles medium (DMEM) and Ham's F12 medium (F12) (Gibco BRL, Grand Island, NY) supplemented with 10% whole fetal bovine serum (FBS) and incubated at 37°C in an atmosphere containing 5% CO₂. Confluent plates of 293 cells were passaged at a ratio of 1:5; and were transfected at 60% confluency with plasmids containing TNFR-IgG1 glycosylation variants by the calcium phosphate method (Graham and Van Der Eb (1973) Virol. 52:456-467). For expression of TNFR-IgG1 variants in CHO cell lines, the genes encoding TNFR-IgG1 glycosylation site mutants were cloned into the pSVI6B5 expression vector. These plasmids were then co-transfected into CHO cells deficient in the production of dihydrofolate reductase (dhfr) along with a plasmid (pFD11) containing a cDNA encoding murine dhfr. The transfected cells were selected for the ability to grow in culture medium deficient in the production of glycine, hypoxanthine and thymidine. Resulting colonies were picked and then selected for growth in varying concentration of methotrexate. Stable cell lines expressing TNFR-IgG1 glycosylation site mutants were grown in 10 liter mini-fermentors, and growth conditioned cell culture medium was harvested for affinity purification (described below).

Metabolic Labeling and Immunoprecipitation. Two days post-transfection, the culture medium was removed from the transfected 293 cells and the cell monolayer washed twice with phosphate buffered saline (PBS). Cells were incubated in methionine and cysteine free DMEM and supplemented with ProMix 35S-Cell Labelling Mix (Amersham, Arlington Hts, IL) (100(Ci/mL). The cells were labeled 8-16 hours at 37 °C in an atmosphere of 5% CO₂. After labeling, the cell supernatants were removed, centrifuged at 4000 rpm for 5 minutes, and 1 mL was aliquoted for immunoprecipitation experiments. The labeled cells were washed three times with PBS, lysed directly on the culture dishes with cell lysis buffer (PBS containing 3% NP-40), and centrifuged at 14,000 x g for 5 minutes. The lysate was transferred to a fresh tube, and 200 µL was removed for immunoprecipitation. Immunoprecipitation of both supernatants and lysates was accomplished by addition of 30 µL of *S. aureus* Protein A (Pharmacia Inc., Piscataway, NJ). After a short incubation period on ice (10-15 minutes) the Protein A/TNFR-IgG1 complexes were sedimented by centrifugation at 14,000 x g for 1 minute, washed in wash buffer (PBS, 1% NP-40, 0.1% sodium dodecyl

(1)
text moved from p. 16
of the original specification
to page 21 of the substitute
specification

(2) -16-
text moved from page
16 of original specification
to page 22 of the substitute
specification

(3)
text is moved
from p. 16
of original
specification
to page 23 of
substitute specification

(1) sulfate (SDS)), and resuspended in 2X sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer containing 5% 2-mercaptoethanol (2-ME). The immunoprecipitated proteins were resolved by SDS-PAGE using 10% Tris-Glycine polyacrylamide gels (Novex, Inc., San Diego, CA). Proteins were visualized by autoradiography and mobilities were calculated with reference to ¹⁴C-Methylated Rainbow Colored Protein Molecular Weight Markers (Amersham, Arlington Heights, IL). Proteins were quantitated by densitometric scanning of autoradiographs using the Personal Densitometer (Molecular Dynamics, Sunnyvale, CA).

Pulse Chase Analysis. 48 hours post-transfection, cells were pulse-labeled with ProMix ³⁵S-Cell Labeling Mix (500(Ci /mL) for 15 minutes. The labeling medium was then removed and the cell monolayer was washed at room temperature with PBS. Fresh medium (DMEM/F12 + 10% FBS) was then added, and cells were harvested at various time-points. For harvesting, plates were chilled on ice; supernatants were removed, and the cell monolayer was washed once with PBS. Cells were then lysed with 1mL of lysis buffer. Lysate and supernatant samples were aliquoted and immunoprecipitated as described above.

Purification of TNFR-IgG glycosylation site mutants. Growth conditioned culture medium from cultures at 10 L CHO cells expressing TNFR-IgG1 glycosylation site mutations were purified by affinity chromatography on immobilized *S. aureus* protein A using a method described previously (Chamow *et al.* (1994) *J. Immunol.* 153:4268-4280). Four TNFR-IgG1 variants were purified: NNNN, NNQQ, NSNQ, and QSNQ. Briefly, purification was involved the following steps. (I) Prior to sample loading, the Protein A column was equilibrated with 20 mM Tris buffer, 15 mM NaCl (pH 7.4). After the growth conditioned cell culture medium was loaded onto the column, the column was sequentially washed with the following buffers: 20 mM Tris buffer, 150 mM NaCl (pH 7.4); 20 mM Tris buffer, 500 mM TMAC (pH 7.4); and 20 mM Tris buffer (pH 7.4). The glycosylation site mutants were eluted with 50 mM citric acid, 20% (w/v) glycerol (pH 3.0) and the elution pools were subsequently adjusted to pH 6.0 using 1.0 M sodium citrate. Finally, the eluates were buffer exchanged by gel filtration chromatography into PBS (pH 7.4). The purified mutants were analyzed using SDS-PAGE (12.5%) with Coomassie blue staining.

TNF binding assay. The binding of TNF to TNFR-IgG1 and TNFR-IgG1 glycosylation site mutants was determined using a competitive binding immunoassay similar to that described by Ashkenazi, *et al.* (1991) *supra*. Briefly, microtiter plates were coated with affinity purified goat antibodies to human IgG Fc domain. Purified TNFR-IgG1 or TNFR-IgG1 glycosylation site mutants were captured on the plates and then reacted with varying concentrations of unlabeled TNF (0.8 to 800 nM) and a fixed amount of (¹²⁵I)-labeled TNF (0.05 nM). After washing the amount of TNF remaining bound to the wells of the microtiter plates was determined with a gamma counter. Data were fit using a four parameter curve. The effective concentration of unlabeled TNF that resulted in half maximal (50%) binding of (¹²⁵I)-labeled TNF to TNFR-IgG1 glycosylation mutants was reported as EC₅₀ values.

35

EXAMPLE 1

TNFR-IgG1 is a chimeric protein constructed by fusing the extracellular domain of the receptor for TNF alpha with sequences encoding the Fc domain and hinge region of IgG1 (Ashkenazi *et al.*, (1991) *supra*). The chimeric protein (Figure 1) contains four N-linked glycosylation sites: three located in the TNFR region (positions 14, 105, and 111) and one in the Fc domain (position 248). Previous studies have shown that TNFR- }

[1]
1 text moved from
p. 17 of original specification
to page 23 of substitute
specification

(2)
-17- 1 text moved from p. 17
of original specification
to page 24 of substitute
specification

(1) IgG1 is secreted as a homodimer, binds to TNF alpha with high affinity, and has potent anti-inflammatory activity in vivo.

Pulse-chase experiments were carried out to characterize the secretion efficiency of TNFR-IgG1. In these studies, 293 cells were transiently transfected with a calcium phosphate precipitated plasmid (pRK.TNFR-IgG1) and cultured for 2 days. The cells were pulse-labeled with (³⁵S)- methionine, and samples were collected at various time points. Immunoprecipitation studies (Figure 2) indicated that TNFR-IgG1 first appeared in the cell culture medium approximately 1 hr after pulse labeling, and that the amount of secreted protein progressively increased over the entire 24 hr observation period. These studies also showed that a significant fraction of the TNFR-IgG1 synthesized during a 15 minute pulse labeling was retained inside the cells. Densitometric analysis of these data (Figure 3A) demonstrated that only about 50% of the pulse-labeled protein was secreted from the cell during a 24 hr period, and that labeled precursor appeared to remain in a stable intracellular pool for more than 24 hr. The kinetics and pattern of secretion observed for TNFR-IgG1 were similar to those previously reported for two other secreted variants of membrane glycoproteins (Berman *et al.*, (1989) J. Virol. 63: 3489-3498) suggesting that secretion of TNFR-IgG1 was similarly inefficient.

Endoglycosidase digestion and immunofluorescence studies similar to those described by Machamer and Rose (1988) J. Biol. Chem. 263:5955-5960) showed that the intracellular TNFR-IgG1 could be localized to the ER and was sensitive to endoglycosidase H digestion (endoH). These studies further showed that secreted TNFR-IgG1 was resistant to endo H digestion and sensitive to neuraminidase digestion. Together these results suggested that the intracellular TNFR-IgG1 accumulated in the endoplasmic reticulum (ER) and possessed the characteristic high mannose form of N-linked carbohydrate, whereas the secreted protein possessed terminal sialation acquired in the trans-Golgi apparatus (tGA).

EXAMPLE 2

Deletion of glycosylation sites can impair secretion of TNFR-IgG1. To examine the effect of sequential deletion of glycosylation sites on the secretion of TNFR-IgG1, further experiments were carried out with a series of glycosylation mutants (Table 1).

(1)

1 text moved from p. 18
of the original specification
to page 24 of the substitute
specification 1

(2)

1 text moved
from p. 18 of
the original specification
to page 25 of the
substitute specification }

(1) **Table 1**
Summary of TNFR1-IgG1 Glycosylation Mutants

	<u>Amino acid position</u>				<u>Secretion Efficiency</u>
	14	105	111	248	
5	N	N	N	N	+++
	Q	N	N	N	++
	N	Q	Q	N	+
	N	N	N	Q	+++
10	N	N	Q	N	+
	N	Q	N	N	-
	Q	N	N	Q	+
	N	N	Q	Q	+
	Q	Q	Q	N	+/-
15	Q	Q	Q	Q	-
	N	S	N	N	+++
	N	N	S	N	+
	N	D	D	N	+
	N	K	K	N	++
20	N	S	S	N	-
	N	R	R	N	+
	N	T	T	N	+/-
	Q	S	N	Q	-
	N	D	D	Q	+
25	N	K	K	Q	++

In these studies, mutagenesis primers were designed to replace the codon specifying asparagine (N) in the N-linked carbohydrate attachment sequon, N-X-S/T, with codons specifying glutamine (Q). Because glycosylation sites 2 and 3 in TNFR-IgG1 are only a few amino acids apart (residues 105 and 111), a single mutagenesis primer could be used to mutate both sites simultaneously. We found that all of the glycosylation mutants were expressed, but there were significant differences in secretion efficiency (Figure 4A). Removal of the fourth glycosylation site (residue 248), located in the Fc domain of TNFR-IgG1 (NNNQ) had no effect on secretion, relative to wild type TNFR-IgG1 (NNNN). In contrast, removal of glycosylation sites 2 and 3 (NQQN) resulted in a nearly complete blockade of secretion. Deletion of the first glycosylation site (QNNN) also blocked secretion, however in this case secretion was approximately 35% of that seen with the fully glycosylated protein. Removal of the first three glycosylation sites (QQQN) completely inhibited secretion as did removal of all four glycosylation sites (QQQQ).

Further mutants were constructed (Table 1) to study, independently, the influence of glycosylation sites 2 and 3 on secretion. It was found that removal of glycosylation site 3 alone (NNQN) allowed for secretion at approximately 10% of level seen with the fully glycosylated protein, whereas deletion of glycosylation site 2 alone (NQNN) completely abolished secretion (Figure 4B). Deletion of glycosylation sites

(1)
 1 text moved from
 p. 19 of the original
 specification to page 26
 of substitute specification

(2)
 1 text moved from page
 19 of the original specification
 to page 27 of the substitute
 specification

(1) 3 and 4 (NNQQ) resulted in a secretion efficiency (Figure 4C) that was similar to the NNQN mutant but lower than the NNNQ mu. (Figure 4B). Deletion of glycosylation sites 1-4 (QNNQ) resulted in significantly lower levels of secretion (Figure 4C) than was observed with the QNNN and NNNQ mutants alone (Figure 4A).

5

EXAMPLE 3

Nature of the amino acid side chain used to mutate N linked glycosylation site can effect secretion efficiency. Additional studies were carried out to determine if the nature of the amino acid side chain used for replacement of the N residue in the sequence creating an N-linked glycosylation site affected secretion efficiency. Each N-linked oligosaccharide chain can possess two to four sialic acid residues, depending on the antennarity of the high mannose precursor. We reasoned that replacement of N at N-linked glycosylation sites with charged residues (e.g. aspartic acid, glutamic acid, lysine, arginine) might have less effect on conformation than replacement with hydrophilic uncharged side-chains (e.g. glutamine, threonine, serine). We found that replacement of the N residues at glycosylation sites 2 and 3 with acidic, aspartic acid residues (NDDN) or basic, lysine residues (NKKN) allowed for better secretion (Figure 4B) than the uncharged glutamine residues in the (NQQN) construct (Figure 4A); however, the amount of protein secreted was far less than that observed with the wild-type TNFR-IgG1 protein. Replacement of asparagine at sites 2 and 3 with arginine (NRRN), also gave better secretion than the NQQN mutant, but the total amount of secreted protein appeared to be less compared to the NDDN or NKKN mutants (Figure 4D).

We next considered the effect of uncharged, hydrophilic side-chains, serine and threonine, on the secretion efficiency of TNFR-IgG1. We found that replacement of glycosylation sites 2 and 3 with serine (NSSN) or threonine (NTTN), like the glutamine mutants (NQQN) completely inhibited secretion (Figure 4D). However, single substitutions of serine for asparagine at glycosylation sites 2 and 3 with serine gave different results (Figure 4D). The replacement of serine for asparagine at glycosylation site 2 (NSNN) allowed for better secretion than any of the other amino acid replacements examined at this position. In contrast, replacement of serine for asparagine at glycosylation site 3 (NNSN) resulted in secretion similar to that observed in the NNQN mutant (Figure 4B). }

(1)
1 text moved from
p.20 of the original
specification to page 27
of the substitute specification 1

(2)
1 text moved from
p.20 of the original
specification to p.
28 of substitute
specification 3

EXAMPLE 4

Triple deletion mutants. To investigate the effect of glycosylation site 4 in combination with sites 1-3, a series of mutants were constructed where three of the four glycosylation sites were deleted (Table 1). It was found that the NDDQ, the NKKQ, the NDDN and NKKN mutants were all secreted from transfected cells (Figure 4C). However, in all four cases the amount of protein secreted was a small fraction (approximately 10%) of the amount secreted by fully glycosylated TNFR-IgG1. Thus, removal of glycosylation site 4 did not alter the secretion efficiency of variants where asparagine residues at glycosylation sites 2 and 3 were replaced by lysine or aspartic acid. A final mutant where three of the four glycosylation sites were deleted (QSNQ) was also examined (Table 1, Figure 5). This variant accumulated intracellularly and was not secreted.

EXAMPLE 5

Secretion efficiency of immunoadhesins can be improved by altering the signal sequence. Studies were performed to demonstrate that the yield and secretion efficiency of a representative immunoadhesin, TNFR-IgG1, from stably transfected CHO cells can be improved by replacement of the TNFR-IgG1 signal sequence with that of human tissue plasminogen activator (tPA). In these studies the signal sequences of herpes simplex virus type 1 glycoprotein D (HSV gD-1), Met-Gly-Gly-Thr-Ala-Ala-Arg-Leu-Gly-Ala-Val-Ile-Leu-Phe-Val-Val-Ile-Val-Gly-Leu-His-Gly-Val-Arg-Gly (SEQ ID NO: 9), recombinant human DNase, Met-Arg-Gly-Lys-Leu-Leu-Gly-Ala-Leu-Leu-Ala-Leu-Ala-Ala-Leu-Leu-Gln-Gly-Ala-Val-Ser (SEQ ID NO: 10), HER-2, Met-Gly-Trp-Ser-Cys-Ile-Ile-Leu-Phe-Leu-Val-Ala-Thr-Ala-Thr-Gly-Val-His-Ser (SEQ ID NO: 11), TNFR, Met-Gly-Leu-Ser-Thr-Val-Pro-Asp-Leu-Leu-Leu-Pro-Leu-Val-Leu-Leu-Glu-Leu-Leu-Val-Gly-Ile-Tyr-Pro-Ser-Gly-Val-Ile-Gly (SEQ ID NO: 2) (Ashkenazi *et al.*, (1991) Proc. Natl. Acad. Sci. 88:10535-10539), and t-PA (SEQ ID NO: 1) were operably linked to the nucleic acid sequence encoding TNFR1-IgG1 and the secretion kinetics were followed. The results indicated an increase in amount of TNFR-IgG1 that could be recovered from the supernatant as well as an improvement in the secretion kinetics (2 hrs and 24 hrs).

To determine whether the tPA signal/pro-sequence improved yield by increasing the efficiency of intracellular transport, a plasmid (pRK.tPA-TNFR-IgG1) was constructed for transient transfection studies in 293 cells. Pulse-chase studies (Figure 2, Figure 3A and B) showed that replacement of the TNFR signal sequence with the tPA signal/pro sequence resulted in a significant improvement in secretion efficiency. Thus, after 24 hours, approximately 70-80% of the pulse-labeled TNFR-IgG1 was secreted into the cell culture medium when the tPA signal/pro sequence was included, whereas only 50-60% of the protein was secreted using the wild-type TNFR signal sequence. The increased efficiency of secretion achieved with the tPA signal/pro sequence was apparent from the kinetics of secretion of TNFR-IgG1 (Figures 2, Figures 3A and B). When the TNF signal/pro sequence was used, only 40% of the pulse-labeled TNFR-IgG1 was secreted in 2-4 hr after pulse labeling. However when the TNF signal sequence was replaced with the tPA signal/pro sequence approximately 60% of the TNFR-IgG synthesized with the TNFR signal sequence was secreted in this time frame.

Studies of the biosynthesis of tPA have shown that the N terminal processing of tPA is complex and involves co-translational cleavage of a 21 amino acid signal sequence, post-translation cleavage of an 11 amino acid pro-sequence at a furin cleavage site, and extracellular cleavage of a 3 amino acid, N-terminal peptide by an undefined exopeptidase (Figure 1). This complex strategy for N terminal processing of TNFR-IgG1 mutants is supported by our results showing that intracellular TNFR-IgG1 variants possessing the tPA signal/pro sequence possessed higher molecular weights than the corresponding secreted proteins (Figure 5A).

(1)
1 text moved from p
21 of original specification
to page 28 of substitute
specification

-21-

(2)
1 text moved from
p. 21 of the original
specification to p. 29
of the substitute specification

(1) Since furin is known to be localized in the trans-GA, the pro-sequence would not be expected to be removed until the tPA-TNFR precursor has been transported from the ER to the trans-GA. Endoglycosidase digestion studies and immunofluorescence studies have provided data consistent with an ER localization of intracellular variants of tPA.TNFR-IgG1.

5

EXAMPLE 6

Secretion efficiency of glycosylation site mutants can be improved by altering the signal sequence. To determine whether signal sequence exchange could improve the secretion efficiency of the TNFR-IgG1 glycosylation site mutants described in Figure 4, the TNFR signal sequence was deleted and replaced by the tPA signal/pro sequence. It was found (Table 2, Figure 5) that the signal sequence exchange resulted in a marked increase in secretion efficiency of these glycosylation site mutants. (2)

10

Table 2

Effect of tPA Signal Sequence or Secretion of TNFR1-IgG1 Glycosylation Mutants

15

Mutant	% Secretion Efficiency*		EC50 for TNF Binding†
	TNFR.ss	tPA.ss	(nM)
NNNN	50	70	6.66 +/- 0.73
NNQQ	20	70	4.74 +/- 0.48
NSNQ	<5	60	6.94 +/- 0.83
NKKQ	10	40	ND
QSNQ	<5	65	2.34 +/- 0.22
QQQQ	<5	<5	ND

20

* Data represent results from pulse-chase experiments (e.g. Figure 3) where the percentage of pulse-labeled protein secreted in a 24 hr period was measured by scanning densitometry.

25

†Data represent EC50 values for the displacement of (¹²⁵I)-labeled TNF by TNFR-IgG1 glycosylation site mutants (Figure 7).

30

For example, only 10-20 % of the NNQQ mutant was secreted using the TNFR signal sequence, whereas 60-70% of the NNQQ mutant containing the tPA signal/pro sequence was secreted (Figures 3C and D, Figure 5). Similarly, little or none of the QSNQ mutant was secreted containing the TNFR signal sequence, but approximately 60% was secreted from the tPA signal/pro sequence containing variant (Figures 3E and F, Figure 5). Similar improvements in secretion efficiency were observed for the NKKQ and NSNQ mutants (Figure 5). Densitometric analysis of pulse chase experiments (Figure 3) showed that attachment of the tPA signal/pro sequence accelerated the kinetics of intracellular transport as well as increasing the total amount of secreted protein. Although replacement of the tPA /pro sequence could overcome the blockade of protein?

(1)

1 text moved from p 22 of original specification to page 29 of substitute specification

(2)

-22- 1 text moved from p 22 of the original specification to p. 30 of substitute specification

(1) secretion for many of the glycosylation mutants, this strategy was not effective for the fully glycosylated QQQQ glycosylation site mutant (Figure 5). (2)

EXAMPLE 7

Structure and TNF binding activity of TNFR-IgG1 glycosylation mutants. Although the signal sequence exchange strategy described above provided a method that allowed for the secretion of TNFR-IgG1 glycosylation site mutants, we wondered whether the secreted proteins were properly folded. To answer this question, stable CHO cell lines, expressing several of the TNFR-IgG1 glycosylation mutants, were constructed in order to produce sufficient quantities for ligand binding studies. Recombinant proteins representing the NNQQ, NSNQ, and QSNQ mutants were purified from growth conditioned cell culture medium using protein affinity chromatography. It was found (Figure 6) that the glycosylation site mutants, like TNFR-IgG1, associated to form covalent disulfide bonded dimers that were stable in SDS and could be dissociated by the addition of reducing agents (e.g. 2-mercaptoethanol). As expected, the molecular mass of the glycosylation variants correlated with the number of intact glycosylation sites. Thus the variants with two glycosylation sites deleted (NNQQ and NSNQ) were smaller in molecular weight than the wild type (NNNN) proteins and larger in molecular mass than the QSNQ variant the possessed only one glycosylation site.

TNF binding studies were carried out to determine whether the secreted glycosylation variants were folded into a functionally relevant conformation. For this purpose, the three glycosylation mutants illustrated in Figure 6 were evaluated in a binding assay (Figure 7) using (125 I)-labeled TNF by a method similar to that described by Ashkenazi *et al.*. All three mutants bound the (125 I)-labeled TNF with EC_{50} values (Table 2) comparable to that observed for fully glycosylated TNFR-IgG1. These studies suggested that neither glycosylation sites nor the tPA signal/pro sequence affected the interaction of TNFR-IgG1 with its ligand.

EXAMPLE 8

To determine the influence of the tPA propeptide on secretion kinetics of tPA/TNFR-IgG1 a construct was generated containing the 29aa TNFR signal sequence (SEQ ID NO: 2) and a 13 amino acid t-PA propeptide (SEQ ID NO: 7) having the sequence Met-Gly-Leu-Ser-Thr-Val-Pro-Asp-Leu-Leu-Leu-Pro-Leu-Val-Leu-Leu-Glu-Leu-Leu-Val-Gly-Ile-Tyr-Pro-Ser-Gly-Val-Ile-Gly-Ser-Gln-Glu-Ile-His-Ala-Arg-Phe-Arg-Arg-Gly-Ala-Arg (SEQ ID NO: 8) was prepared. From RIP experiments SEQ ID NO: 8 was shown to have similar $t^{1/2max}$ and percent secretion at 24 hours to that of tPA/TNFR-IgG1 (Figure 8 A-C). Endo H digest also reveal similar secretion kinetics to that of tPA/TNFR-IgG1, where approximately 1/3 of the lysate is endo H resistant between 10 and 30 minutes and is probably secreted within 30 minutes, as opposed to the wild type TNFR-IgG in which very little of the lysate is Endo H resistant and the band does not decrease over time. This evidence strongly indicates that the decrease in $t^{1/2max}$ and percent secretion at 24 hours for tPA/TNFR-IgG1 is due to the presence of the 13 amino acid propeptide. This is supported by transient expression data, wherein 14 yields similar total expression as well as specific productivity.

(1)
1 text moved from
p. 23 of original
specification to
p. 30 of substitute
specification 1

(2)
1 text moved from
p. 30 of original
specification to
p. 31 of substitute
specification 2

(3)
3 text moved from
p. 30 of original
specification
to p. 32 of
substitute specification 3

(1)

WHAT IS CLAIMED IS:

1. A DNA construct comprising:
a first DNA segment encoding a precursor polypeptide comprising a pro-sequence of a mammalian t-PA; and
a second DNA segment operably linked to the first DNA sequence, the second DNA sequence encoding a heterologous glycoprotein.
2. The DNA construct of claim 1 wherein the heterologous glycoprotein is an immunoadhesin.
3. The DNA construct of claim 2 wherein the immunoadhesin is a TNF receptor immunoadhesin.
4. The DNA construct of claim 3 wherein the TNF receptor immunoadhesin is TNFR1-IgG1.
5. The DNA construct of claim 1 wherein the DNA encoding the mammalian t-PA pro-sequence is operably linked to a pre-sequence other than a mammalian t-PA pre-sequence.
6. The DNA construct of claim 5 wherein the heterologous glycoprotein is and immunoadhesin.
7. The DNA construct of claim 6 wherein the immunoadhesin is a TNF receptor immunoadhesin.
8. The DNA construct of claim 7 wherein the TNF receptor immunoadhesin is TNFR1-IgG1.
9. The DNA construct of claim 5 wherein the mammalian t-PA pro-sequence is operably linked a pre-sequence associated with the native heterologous polypeptide.
10. The DNA construct of claim 9 wherein the heterologous glycoprotein is a TNF receptor immunoadhesin and the pre-sequence is a pre-sequence of a mammalian TNF receptor. (2)
11. The DNA construct of claim 10 wherein the mammalian t-PA pro-sequence is SEQ ID NO: 7.
12. The DNA construct of claim 11 wherein the pre-sequence is SEQ ID NO: 8.
13. The DNA construct of claim 12 wherein the TNF receptor immunoadhesin is TNFR1-IgG1.
14. A DNA construct comprising:
a first DNA segment encoding a precursor peptide; and
a second DNA segment operably linked to the first DNA sequence, the second DNA sequence encoding a heterologous glycosylation site variant glycoprotein. }

(1)

1 text moved from p 24
of the original specification
to p. 33 of substitute
specification

(2)

-24-

1 text moved from
p. 24 of original
specification to p.
34 of substitute specification

(1)

15. The DNA construct of claim 14 further comprising one or more additional DNA segments operably linked to the first and second DNA segments.

16. The DNA construct of claim 14 wherein the precursor peptide comprises the pro-sequence of a mammalian t-PA.

17. The DNA construct of claim 16 wherein the pro-sequence is a human t-PA pro-sequence.

18. The DNA construct of claim 17 wherein the pro-sequence is SEQ ID NO: 5.

19. The DNA construct of claim 16 further comprising a pre-sequence of a mammalia t-PA.

20. The DNA construct of claim 19 wherein the pre-sequence is a human t-PA pre-sequence.

21. The DNA construct of claim 20 wherein the pre-sequence is SEQ ID NO: 3.

22. The DNA construct of claim 21 wherein the precursor peptide is SEQ ID NO 1.

23. The DNA construct of claim 14 wherein the heterologous glycosylation site variant is a glycosylation site addition variant. (2)

24. The DNA construct of claim 14 wherein the heterologous glycosylation site variant is a glycosylation site deletion variant.

25. The DNA construct of claim 24 wherein the heterologous glycosylation site variant is an immunoadhesin.

26. The DNA construct of claim 25 wherein the immunoadhesin is TNFR-IgG.

27. The DNA construct of claim 26 wherein the TNFR-IgG is TNFR1-IgG1.

28. The DNA construct of claim 27 wherein the TNFR1-IgG1 has an N-linked glycosylation site selected from the group consisting of amino acid positions 14, 105, 111 and 248 deleted.

29. The DNA construct of claim 28 wherein the TNFR1-IgG1 has the N-linked site at 14 deleted.

30. A cultured eukaryotic host cell comprising a DNA construct comprising:

a first DNA segment encoding a precursor peptide corresponding to a mammalian tissue plasminogen activator secretory peptide; and

a second DNA segment operably linked to the first DNA sequence, the second DNA sequence encoding a heterologous glycosylation site variant. Z

(2)

(1)
1 text moved from p.25
of the original specification
to page 34 of substitute specification 1

1 text moved from
p.25 of original
specification to p.35
of substitute specification }

(1) 31. The cultured eukaryotic host cell of claim 30 wherein the host cell is a rodent host cell.

32. The cultured eukaryotic host cell of claim 31 which is a CHO cell.

33. A method of producing a polypeptide which has been altered to delete one or more native N-linked glycosylation sites comprising the steps of

(a) culturing a eukaryotic host cell comprising a DNA construct comprising:

a first DNA segment encoding a precursor peptide corresponding to a mammalian tissue plasminogen activator signal-pro peptide; and (2)

a second DNA segment operably linked to the first DNA sequence, the second DNA sequence encoding a heterologous glycosylation site deletion variant polypeptide;

wherein the eukaryotic host cell express the first and second DNA segments and the polypeptide is secreted from the cell; and

(b) recovering the polypeptide so produced. 3

(1)

1 text moved from p 26
of original specification
to p. 35 of substitute specification 1

(2)

1 text moved from p 26
of original specification
to p 36 of the substitute specification ?

Abstract of the Disclosure

5

DNA constructs, host cells and production methods are disclosed for the expression and recovery of polypeptides, especially those altered to have one or more glycosylation sites added or deleted. The DNA constructs, host cells and methods provided herein employ a DNA segment corresponding to a mammalian tissue plasminogen activator signal and/or pro peptide. }

(1)

1 text moved from p 27 of
original specification to p. 37
of substitute specification

5 <110> Ashkena .. A.
 Berman, P.
 Brousseau, D.
 Etcheverry, T.

10 <120> SECRETION OF GLYCOSYLATION MUTANTS
 <130> P1055R1
 <141> 1999-04-14
 <150> US 60/082,002
 15 <151> 1998-04-16
 <150> US 60/
 <151> 1999-03-08
 20 <160> 13
 <210> 1
 <211> 35
 <212> PRT
 25 <213> Homo sapiens
 <400> 1
 Met Asp Ala Met Leu Arg Gly Leu Cys Cys Val Leu Leu Leu Cys
 1 5 10 15
 30 Gly Ala Val Phe Val Ser Pro Ser Gln Glu Ile His Ala Arg Phe
 20 25 30
 Arg Arg Gly Ala Arg
 35 35
 <210> 2
 <211> 29
 <212> PRT
 40 <213> Homo sapiens
 <400> 2
 Met Gly Leu Ser Thr Val Pro Asp Leu Leu Leu Pro Leu Val Leu
 1 5 10 15
 45 Leu Glu Leu Leu Val Gly Ile Tyr Pro Ser Gly Val Ile Gly
 20 25 29
 50 (1) | <210> 3
 <211> 21
 <212> PRT
 <213> Homo sapiens
 <400> 3
 55 Met Asp Ala Met Leu Arg Gly Leu Cys Cys Val Leu Leu Leu Cys
 1 5 10 15
 Gly Ala Val Phe Val Ser
 20 21
 60 <210> 4
 <211> 11
 <212> PRT
 <213> Homo sapiens
 65 <400> 4
 Pro Ser Gln Glu Ile His Ala Arg Phe Arg Arg |
 1 5 10 11

(1)
 Move text from
 p.1 of Seq. Listing
 to p.2 of Seq. Listing in Substitute Specification

(1) <400> 10
 Met Arg Gly s Leu Leu Gly Ala Leu Leu Ala I ; Ala Ala Leu
 1 5 10 15

5 Leu Gln Gly Ala Val Ser (2)
 20 21

<210> 11
 <211> 19
 10 <212> PRT
 <213> Homo sapiens

<400> 11
 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr
 15 1 5 10 15

Gly Val His Ser
 19

20 <210> 12
 <211> 22
 <212> PRT
 <213> Homo sapiens

25 <400> 12
 Met Asp Ala Met Leu Arg Gly Leu Cys Cys Val Leu Leu Leu Cys
 1 5 10 15

Gly Ala Val Phe Val Ser Pro
 30 20 22

<210> 13
 <211> 10
 <212> PRT
 35 <213> Homo sapiens

<400> 13
 Ser Gln Glu Ile His Ala Arg Phe Arg Arg 2
 1 5 10 2

40

(1)
 1 text moved from p.3
 of original seq. listing to
 p.3 of substitute specification
 Seq. Listing)

(2)
 1 text is moved from
 p.3 of the original
 Seq. Listing to
 p.4 of the substitute
 Seq specification
 Sequence Listing?